MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry.
CISH
FISH
HIV
MYC gene
plasmablastic lymphoma
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
30
12
2020
received:
09
09
2020
accepted:
12
01
2021
pubmed:
16
1
2021
medline:
15
12
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
We utilised chromogenic and fluorescence in-situ hybridisation (CISH and FISH) to evaluate MYC gene copy numbers and rearrangements within HIV-associated plasmablastic lymphomas (PBLs). Thereafter, clinicopathological features were explored retrospectively. Sixty-seven (n = 67) patients were included and the HIV seropositive status was confirmed in 98% (63 of 64) with a median viral load of 55 587 (IQR 273 582) copies/ml and median CD4 count of 170 (IQR 249) cells/µl. The mean age was 41 ± 10.1 years and females comprised 54%. PBL was documented predominantly at extra-oronasal topographic regions. Starry-sky (SS) appearance was evident in 33% in association with monomorphic morphology (P-value 0.02). c-MYC protein was expressed in 81% and latent EBV infection was detected in 90%. EBER ISH-positive status and MYC rearrangement occurred in 67% of HIV PBL. MYC aberrations included MYC rearrangement (70%), low-level increase in MYC gene copy numbers (43%), concurrent MYC rearrangement and increased MYC gene copy numbers (49%) as well as low-level chromosome 8 polysomy (6%). MYC aberrations in HIV PBLs were significantly associated with SS appearance (P -0.01), monomorphic morphology (P - 0.03), c-MYC protein expression ≥40% (P - 0.03) and mortality (P - 0.03). There was advanced stage (Ann Arbor III/IV) at presentation (77%) and the median overall survival for HIV PBL was 75 days (95% CI 14-136). Majority of the HIV-associated PBL tumours harbour MYC aberrations. Due to the persistently inferior survival outcome of HIV-associated PBL in the era of antiviral treatment, targeted and/or intensified therapy of oncogenic MYC may need to be explored in future.
Substances chimiques
MYC protein, human
0
Proto-Oncogene Proteins c-myc
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-95Subventions
Organisme : University of the Witwatersrand, Faculty of Health Sciences, Seed Funding
ID : 001 251 8462101 5121105 000000 0000000000 4550
Organisme : NHLS Research Trust
ID : 004_ 94538
Organisme : University of the Witwatersrand, Faculty of Health Sciences Research Committee, Individual Grant:
ID : 001.283.8462101.5121105.5152
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Morscio J, Dierickx D, Nijs J et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am. J. Surg. Pathol. 2014; 38; 875-886.
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015; 125; 2323-2330.
Patel M, Philip V, Omar T et al. The impact of human immunodeficiency virus infection (HIV) on lymphoma in South Africa. J. Cancer Ther. 2015; 6; 527-535.
Schommers P, Wyen C, Hentrich M et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS. 2013; 27; 842-845.
Meer S, Perner Y, McAlpine ED et al. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area. Histopathology 2020; 76; 212-221.
Arora N, Eule C, Gupta A et al. Clinicopathologic features, management, and outcomes of plasmablastic lymphoma: A 10-year experience. Am. J. Hematol. 2019; 94; E127-E129.
Taddesse-Heath L, Meloni-Ehrig A, Scheerle J et al. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod. Pathol. 2010; 23; 991-999.
Castillo JJ, Furman M, Beltrán BE et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012; 118; 5270-5277.
Valera A, Balagué O, Colomo L et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am. J. Surg. Pathol. 2010; 34; 1686-1694.
Liu Z, Filip I, Gomez K et al. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT Pathway. Blood Cancer Discov. 2020; 1; 112.
Valentino C, Kendrick S, Johnson N et al. Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. Am. J. Clin. Pathol. 2013; 139; 242-254.
Stasik CJ, Nitta H, Zhang W et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010; 95; 597-603.
Delecluse HJ, Anagnostopoulos I, Dallenbach F et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997; 89; 1413-1420.
Tchernonog E, Faurie P, Coppo P et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann. Oncol. 2017; 28; 843-848.
Alli N, Meer S. Head and neck lymphomas: A 20-year review in an Oral Pathology Unit, Johannesburg, South Africa, a country with the highest global incidence of HIV/AIDS. Oral Oncol. 2017; 67; 17-23.
Zuze T, Painschab MS, Seguin R et al. Plasmablastic lymphoma in Malawi. Infect. Agent Cancer. 2018; 13; 22.
World Health Organisation. Understanding the modes of transmission model of new HIV infection and its use in prevention planning 2012 [Available: https://www.who.int/bulletin/volumes/90/11/12-102574/en/]. (accessed 13/03/2021)
Loghavi S, Alayed K, Aladily TN et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J. Hematol. Oncol. 2015; 8; 65-65.
Bibas M, Antinori A. EBV and HIV-related lymphoma. Mediterr. J. Hematol. Infect. Dis. 2009; 1; e2009032.
Ivanov X, Mladenov Z, Nedyalkov S et al. Experimental investigations into avian leucoses. Transmission, haematology and morphology of avian myelocytomatosis. Bulletin de Institut de Pathology Comparative Animaux. 1964; 10; 5-38.
Lautenberger JA, Schulz RA, Garen CF et al. Molecular cloning of myelocytomatosis virus (MC29) transforming sequences. Proc. Natl Acad. Sci. USA 1981; 78; 1518-1522.
Bishop JM. Retroviruses. Annu. Rev. Biochem. 1978; 47; 3548.
Sheiness D, Bishop JM. DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J. Virol. 1979; 31; 514-521.
Vennstrom B, Sheiness D, Zabielski J, Bishop M. Isolation and characterization of c-myc, a cellular omolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J. Virol. 1982; 42; 773-779.
Miller DM, Thomas SD, Islam A et al. c-Myc and cancer metabolism. Clin. Cancer Res. 2012; 18; 5546-5553.
Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod. Pathol. 2017; 30; 85-94.
Miao L, Guo N, Feng Y et al. High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. Histopathology 2020; 76; 201-211.
Wolff AC, Hammond MEH, Allison KH et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 2018; 36; 2105-2122.
Schildhaus H-U, Deml K-F, Schmitz K et al. Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. Mod. Pathol. 2013; 26; 1468-1477.
Witte HM, Hertel N, Merz H et al. Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients. Blood Cancer J. 2020; 10; 63.
van Rijk A, Svenstroup-Poulsen T, Jones M et al. Double-staining chromogenic in situ hybridization as a useful alternative to split-signal fluorescence in situ hybridization in lymphoma diagnostics. Haematologica 2010; 95; 247-252.
Dong HY, Scadden DT, de Leval L et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am. J. Surg. Pathol. 2005; 29; 1633-1641.
Pather S, Mohamed Z, McLeod H et al. Large cell lymphoma: correlation of HIV status and prognosis with differentiation profiles assessed by immunophenotyping. Pathol. Oncol. Res. 2013; 19; 695-705.
Boy SC, van Heerden MB, Babb C et al. Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas. Oral. Oncol. 2011; 47; 883-887.
Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Target. Ther. 2018; 3; 5.